Bicara Therapeutics Files 8-K

TL;DR

Bicara Therapeutics filed an 8-K. Check for updates.

AI Summary

On January 13, 2025, Bicara Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.

Why It Matters

This filing indicates Bicara Therapeutics Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational risks.

Key Players & Entities

• Bicara Therapeutics Inc. (company) — Registrant
• January 13, 2025 (date) — Date of Report
• 001-42271 (company) — SEC File Number
• 116 Huntington Avenue , Suite 703 Boston , MA 02116 (location) — Principal executive offices address

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value BCAX The Nasdaq Global Ma

Filing Documents

• d904889d8k.htm (8-K) — 23KB
• d904889dex991.htm (EX-99.1) — 39KB
• g904889ex99_1p10g1.jpg (GRAPHIC) — 304KB
• g904889ex99_1p11g1.jpg (GRAPHIC) — 289KB
• g904889ex99_1p12g1.jpg (GRAPHIC) — 360KB
• g904889ex99_1p13g1.jpg (GRAPHIC) — 388KB
• g904889ex99_1p14g1.jpg (GRAPHIC) — 342KB
• g904889ex99_1p15g1.jpg (GRAPHIC) — 401KB
• g904889ex99_1p16g1.jpg (GRAPHIC) — 339KB
• g904889ex99_1p17g1.jpg (GRAPHIC) — 368KB
• g904889ex99_1p18g1.jpg (GRAPHIC) — 300KB
• g904889ex99_1p19g1.jpg (GRAPHIC) — 268KB
• g904889ex99_1p1g1.jpg (GRAPHIC) — 246KB
• g904889ex99_1p20g1.jpg (GRAPHIC) — 329KB
• g904889ex99_1p21g1.jpg (GRAPHIC) — 371KB
• g904889ex99_1p22g1.jpg (GRAPHIC) — 255KB
• g904889ex99_1p23g1.jpg (GRAPHIC) — 437KB
• g904889ex99_1p24g1.jpg (GRAPHIC) — 299KB
• g904889ex99_1p25g1.jpg (GRAPHIC) — 313KB
• g904889ex99_1p26g1.jpg (GRAPHIC) — 350KB
• g904889ex99_1p2g1.jpg (GRAPHIC) — 708KB
• g904889ex99_1p3g1.jpg (GRAPHIC) — 401KB
• g904889ex99_1p4g1.jpg (GRAPHIC) — 401KB
• g904889ex99_1p5g1.jpg (GRAPHIC) — 357KB
• g904889ex99_1p6g1.jpg (GRAPHIC) — 385KB
• g904889ex99_1p7g1.jpg (GRAPHIC) — 320KB
• g904889ex99_1p8g1.jpg (GRAPHIC) — 274KB
• g904889ex99_1p9g1.jpg (GRAPHIC) — 357KB
• 0001193125-25-005002.txt ( ) — 12826KB
• bcax-20250113.xsd (EX-101.SCH) — 3KB
• bcax-20250113_lab.xml (EX-101.LAB) — 18KB
• bcax-20250113_pre.xml (EX-101.PRE) — 11KB
• d904889d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2025 Bicara Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-42271 85-2903745 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) 116 Huntington Avenue , Suite 703 Boston , MA 02116 (Address of principal executive offices and zip code) (617) 468-4219 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value BCAX The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item7.01 - Regulation FD Disclosure. Bicara Therapeutics Inc. (the "Company") is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on January 13, 2025. The corporate presentation will also be available in the investor relations section of the Company's website at https://ir.bicara.com/. The information set forth under Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item9.01 - Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Corporate presentation of Bicara Therapeutics Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 13th day of January, 2025. Bicara Therapeutics Inc. By: /s/ Claire Mazumdar Name: Claire Mazumdar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR